Literature DB >> 10027401

Mutations and allelic deletions of the MEN1 gene are associated with a subset of sporadic endocrine pancreatic and neuroendocrine tumors and not restricted to foregut neoplasms.

B Görtz1, J Roth, A Krähenmann, R R de Krijger, S Muletta-Feurer, K Rütimann, P Saremaslani, E J Speel, P U Heitz, P Komminoth.   

Abstract

Endocrine pancreatic tumors (EPT) and neuroendocrine tumors (NET) occur sporadically and rarely in association with multiple endocrine neoplasia type 1 (MEN1). We analyzed the frequency of allelic deletions and mutations of the recently identified MEN1 gene in 53 sporadic tumors including 30 EPT and 23 NET (carcinoids) of different locations and types. Allelic deletion of the MEN1 locus was identified in 18/49 (36.7%) tumors (13/30, 43.3% in EPT and 5/19, 26.3% in NET) and mutations of the MEN1 gene were present in 8/52 (15.3%) tumors (4/30 (13.3%) EPT and 4/22 (18.1%) NET). The somatic mutations were clustered in the 5' region of the coding sequence and most frequently encompassed missense mutations. All tumors with mutations exhibited a loss of the other allele and a wild-type sequence of the MEN1 gene in nontumorous DNA. In one additional patient with a NET of the lung and no clinical signs or history of MEN1, a 5178-9G-->A splice donor site mutation in intron 4 was identified in both the tumor and blood DNA, indicating the presence of a thus far unknown MEN1 syndrome. In most tumor groups the frequency of allelic deletions at 11q13 was 2 to 3 times higher than the frequency of identified MEN1 gene mutations. Some tumor types, including rare forms of EPT and NET of the duodenum and small intestine, exhibited mutations more frequently than other types. Furthermore, somatic mutations were not restricted to foregut tumors but were also detectable in a midgut tumor (15.2% versus 16.6%). Our data indicate that somatic MEN1 gene mutations contribute to a subset of sporadic EPT and NET, including midgut tumors. Because the frequency of mutations varies significantly among the investigated tumor subgroups and allelic deletions are 2 to 3 times more frequently observed, factors other than MEN1 gene inactivation, including other tumor-suppressor genes on 11q13, may also be involved in the tumorigenesis of these neoplasms.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10027401      PMCID: PMC1849990          DOI: 10.1016/S0002-9440(10)65289-3

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  29 in total

1.  Allelic deletions on chromosome 11q13 in multiple endocrine neoplasia type 1-associated and sporadic gastrinomas and pancreatic endocrine tumors.

Authors:  L V Debelenko; Z Zhuang; M R Emmert-Buck; S C Chandrasekharappa; P Manickam; S C Guru; S J Marx; M C Skarulis; A M Spiegel; F S Collins; R T Jensen; L A Liotta; I A Lubensky
Journal:  Cancer Res       Date:  1997-06-01       Impact factor: 12.701

2.  Positional cloning of the gene for multiple endocrine neoplasia-type 1.

Authors:  S C Chandrasekharappa; S C Guru; P Manickam; S E Olufemi; F S Collins; M R Emmert-Buck; L V Debelenko; Z Zhuang; I A Lubensky; L A Liotta; J S Crabtree; Y Wang; B A Roe; J Weisemann; M S Boguski; S K Agarwal; M B Kester; Y S Kim; C Heppner; Q Dong; A M Spiegel; A L Burns; S J Marx
Journal:  Science       Date:  1997-04-18       Impact factor: 47.728

3.  RET proto-oncogene point mutations in sporadic neuroendocrine tumors.

Authors:  P Komminoth; J Roth; S Muletta-Feurer; P Saremaslani; W K Seelentag; P U Heitz
Journal:  J Clin Endocrinol Metab       Date:  1996-06       Impact factor: 5.958

4.  Germline mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states.

Authors:  S K Agarwal; M B Kester; L V Debelenko; C Heppner; M R Emmert-Buck; M C Skarulis; J L Doppman; Y S Kim; I A Lubensky; Z Zhuang; J S Green; S C Guru; P Manickam; S E Olufemi; L A Liotta; S C Chandrasekharappa; F S Collins; A M Spiegel; A L Burns; S J Marx
Journal:  Hum Mol Genet       Date:  1997-07       Impact factor: 6.150

5.  Carcinoid tumors frequently display genetic abnormalities involving chromosome 11.

Authors:  O Jakobovitz; D Nass; L DeMarco; A J Barbosa; F B Simoni; G Rechavi; E Friedman
Journal:  J Clin Endocrinol Metab       Date:  1996-09       Impact factor: 5.958

6.  Localization of the multiple endocrine neoplasia type I (MEN1) gene based on tumor loss of heterozygosity analysis.

Authors:  M R Emmert-Buck; I A Lubensky; Q Dong; P Manickam; S C Guru; M B Kester; S E Olufemi; S Agarwal; A L Burns; A M Spiegel; F S Collins; S J Marx; Z Zhuang; L A Liotta; S C Chandrasekharappa; L V Debelenko
Journal:  Cancer Res       Date:  1997-05-15       Impact factor: 12.701

7.  Somatic mutation of the MEN1 gene in parathyroid tumours.

Authors:  C Heppner; M B Kester; S K Agarwal; L V Debelenko; M R Emmert-Buck; S C Guru; P Manickam; S E Olufemi; M C Skarulis; J L Doppman; R H Alexander; Y S Kim; S K Saggar; I A Lubensky; Z Zhuang; L A Liotta; S C Chandrasekharappa; F S Collins; A M Spiegel; A L Burns; S J Marx
Journal:  Nat Genet       Date:  1997-08       Impact factor: 38.330

8.  Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas.

Authors:  Z Zhuang; A O Vortmeyer; S Pack; S Huang; T A Pham; C Wang; W S Park; S K Agarwal; L V Debelenko; M Kester; S C Guru; P Manickam; S E Olufemi; F Yu; C Heppner; J S Crabtree; M C Skarulis; D J Venzon; M R Emmert-Buck; A M Spiegel; S C Chandrasekharappa; F S Collins; A L Burns; S J Marx; I A Lubensky
Journal:  Cancer Res       Date:  1997-11-01       Impact factor: 12.701

9.  An analysis of 8305 cases of carcinoid tumors.

Authors:  I M Modlin; A Sandor
Journal:  Cancer       Date:  1997-02-15       Impact factor: 6.860

10.  Detection of RET proto-oncogene point mutations in paraffin-embedded pheochromocytoma specimens by nonradioactive single-strand conformation polymorphism analysis and direct sequencing.

Authors:  P Komminoth; E Kunz; O Hiort; S Schröder; X Matias-Guiu; G Christiansen; J Roth; P U Heitz
Journal:  Am J Pathol       Date:  1994-10       Impact factor: 4.307

View more
  29 in total

1.  Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells.

Authors:  A Perren; P Komminoth; P Saremaslani; C Matter; S Feurer; J A Lees; P U Heitz; C Eng
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

2.  Genetic differences in endocrine pancreatic tumor subtypes detected by comparative genomic hybridization.

Authors:  E J Speel; J Richter; H Moch; C Egenter; P Saremaslani; K Rütimann; J Zhao; A Barghorn; J Roth; P U Heitz; P Komminoth
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

3.  Poorly differentiated small cell neuroendocrine carcinoma localized in three different endocrine glands: response to chemotherapy and octreotide LAR.

Authors:  L Tauchmanovà; M Pensabene; I Capuano; I Spagnoletti; P Zeppa; S Del Vecchio; M Mainenti; G De Rosa; A Colao; A Contegiacomo
Journal:  J Endocrinol Invest       Date:  2005-04       Impact factor: 4.256

4.  Gene Amplifications in Well-Differentiated Pancreatic Neuroendocrine Tumors Inactivate the p53 Pathway.

Authors:  Wenwei Hu; Zhaohui Feng; Ippolito Modica; David S Klimstra; Lin Song; Peter J Allen; Murray F Brennan; Arnold J Levine; Laura H Tang
Journal:  Genes Cancer       Date:  2010-05-15

5.  Epigenetic regulation of the lncRNA MEG3 and its target c-MET in pancreatic neuroendocrine tumors.

Authors:  Sita D Modali; Vaishali I Parekh; Electron Kebebew; Sunita K Agarwal
Journal:  Mol Endocrinol       Date:  2015-01-07

6.  Analysis of sporadic neuroendocrine tumours of the enteropancreatic system by comparative genomic hybridisation.

Authors:  H Tönnies; M R Toliat; C Ramel; U F Pape; H Neitzel; W Berger; B Wiedenmann
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

Review 7.  The MEN1 gene and associated diseases: an update.

Authors:  T Tsukada; K Yamaguchi; T Kameya
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

8.  Deletions of 11q22.3-q25 are associated with atypical lung carcinoids and poor clinical outcome.

Authors:  Dorian R A Swarts; Sandra M H Claessen; Yvonne M H Jonkers; Robert-Jan van Suylen; Anne-Marie C Dingemans; Wouter W de Herder; Ronald R de Krijger; Egbert F Smit; Frederik B J M Thunnissen; Cornelis A Seldenrijk; Aryan Vink; Aurel Perren; Frans C S Ramaekers; Ernst-Jan M Speel
Journal:  Am J Pathol       Date:  2011-07-16       Impact factor: 4.307

Review 9.  Neuroendocrine tumors of the pancreas: current concepts and controversies.

Authors:  Michelle D Reid; Serdar Balci; Burcu Saka; N Volkan Adsay
Journal:  Endocr Pathol       Date:  2014-03       Impact factor: 3.943

Review 10.  Potential applications of molecular biology in neuroendocrine tumors.

Authors:  Tommaso Emmer; Marco Volante; Alberto Pagani; Elena Allia; Pellegrino Crafa; Gianni Bussolati
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.